Holen Sie sich die Stockscreener-App
7.95
2.19%
0.17
Schlusskurs vom Vortag:
$7.78
Offen:
$7.76
24-Stunden-Volumen:
64,488
Relative Volume:
3.60
Marktkapitalisierung:
$205.14M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-13.59%
1M Leistung:
+0.00%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$7.76
$8.5315
1-Wochen-Bereich:
$7.76
$9.16
52-Wochen-Spanne:
$7.76
$12.87
Vyome Holdings Inc Stock (HIND) Company Profile
Firmenname
Vyome Holdings Inc
Sektor
Branche
Telefon
949-429-6680
Adresse
1001 CALLE AMANECER, SAN CLEMENTE
Vergleichen Sie HIND mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HIND
Vyome Holdings Inc
|
7.95 | 205.14M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
Vyome Holdings Inc Aktie (HIND) Neueste Nachrichten
Vyome Holdings Announces Positive Interim Data from Phase 2 Study of VT-1953 in Malignant Fungating Wounds (MFW) and Provides Update on MFW market opportunity - biospace.com
Vyome Holdings Inc positive interim data from Phase 2 Study of VT-1953 in malignant fungating wounds - MarketScreener
Vyome’s VT-1953 shows significant reduction in cancer wound odor - Investing.com
Vyome’s VT-1953 shows significant reduction in cancer wound odor By Investing.com - Investing.com UK
Vyome Holdings Completes Merger with Vyome Therapeutics - MSN
Vyome Holdings completes merger with Vyome Therapeutics and files financials - Investing.com
Vyome Holdings, Embryyo Technologies Partner on AI Medtech - Medical Product Outsourcing
Vyome, Embryyo form partnership to pursue AI-enabled medical devices - Medical Economics
US-based Vyome signs MoU with India’s leading medical device innovation studio Embryyo - BioSpectrum India
Vyome And Embryyo Sign MoU To Develop AI-Enabled Medical Devices - Sahyadri Startups
Vyome Holdings, Inc. Signs MoU with Embryyo Technologies - MarketScreener
Vyome, India's Embryyo Sign MOU to Pursue AI Medical Device Market; Shares up Pre-Bell - MarketScreener
Vyome partners with Embryyo to enter AI-enabled medical device market - Investing.com
Vyome Signs MoU with Embryyo, India’s Leading Medical Device Innovation Studio - FinancialContent
Vyome Holdings expands at-the-market offering and appoints new auditor - Investing.com India
Vyome Holdings expands at-the-market offering and appoints new auditor By Investing.com - Investing.com South Africa
Vyome Holdings Amends Equity Distribution Agreement - TipRanks
Vyome Amends Equity Distribution Agreement with ReShape Lifesciences Inc. - AInvest
Vyome enters amendment no. 1 to equity distribution agreement - MarketScreener
Vyome to review strategic options for majority-owned Livechain By Investing.com - Investing.com Australia
Vyome to review strategic options for majority-owned Livechain - Investing.com
Unlocking Value Through Corporate Restructuring: Vyome's Strategic Pivot and the Future of Underfollowed Holdings - AInvest
ReShape Lifesciences® to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update - MarketScreener
Vyome Debuts as HIND on Nasdaq, Strengthening US-India Innovation Ties - YourStory.com
ReShape Lifesciences® to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update - MarketScreener
Vyome lists on Nasdaq as HIND after ReShape merger - The Times of India
HIND Stock Price and Chart — NASDAQ:HIND - TradingView
Vyome Announces Nasdaq Approval of Merger with ReShape Lifesciences, Set to Begin Trading as HIND - MarketScreener
Vyome Therapeutics Completes Merger With ReShape Lifesciences - MarketScreener
Vyome 2025 Q2 Earnings Strong Net Income Surge Despite Revenue Drop - AInvest
Vyome to begin trading as Vyome Holdings under HIND symbol By Investing.com - Investing.com Australia
Health Care Stocks Climb As Deals And Results Grab Attention - Finimize
Why Did ReShape Lifesciences Plunge 8.75% Amid Vyome Merger? - AInvest
ReShape Lifesciences Stock Rocketed 37% Today – Here’s Why By Stocktwits - Investing.com India
Vyome announces Nasdaq approval of merger with ReShape Lifesciences - TipRanks
Vyome therapeutics to list on nasdaq as HIND after reshape merger - Investing.com Canada
Vyome Therapeutics Announces New Board with AI and MIT Ties Ahead of Public Listing - AInvest
Vyome to replace ReShape leadership as it prepares for Nasdaq listing - Investing.com Canada
Vyome to replace ReShape leadership as it prepares for Nasdaq listing By Investing.com - Investing.com South Africa
Vyome Announces New Board of Directors with Deep MIT and AI Ties - FinancialContent
Vyome Therapeutics: A High-Conviction Play at the Intersection of Biotech and AI Innovation - AInvest
ReShape Lifesciences Approves Asset Sale and Merger with Vyome Therapeutics - AInvest
ReShape Shareholders Approve Vyome Merger, Shares to Commence Trading on Nasdaq as Vyome Holdings, Inc. - AInvest
ReShape Lifesciences Announces Shareholder Approval of Merger with Vyome Therapeutics - MarketScreener
ReShape Lifesciences Merger at Critical Stage: Stockholders Must Approve Asset Sale by August 7 - Stock Titan
ReShape Lifesciences Strategic Transformation: Board and Proxy Advisors Unite Behind Vyome Merger - Stock Titan
AUTOCANADA ANNOUNCES CONFERENCE CALL AND WEBCAST DETAILS FOR Q2 2025 FINANCIAL RESULTS - The Globe and Mail
ReShape Lifesciences Slashes Payroll by 23.4% While Fast-Tracking Vyome MergerKey Details Revealed - Stock Titan
ReShape Lifesciences Stock Soars On Distribution Agreement With Recon Supply, Draws Retail Applause By Stocktwits - Investing.com India
ReShape Lifesciences: Intellectual Property and Merger Synergies Position the Company for Long-Term Growth Amid Industry Shifts - AInvest
ReShape Lifesciences And Kiora Pharma Impress Investors, Dollar General Uplifts Outlook - Finimize
Finanzdaten der Vyome Holdings Inc-Aktie (HIND)
Es liegen keine Finanzdaten für Vyome Holdings Inc (HIND) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
1.40%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):